MCID: SCH014
MIFTS: 56

Schistosomiasis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Schistosomiasis

MalaCards integrated aliases for Schistosomiasis:

Name: Schistosomiasis 12 74 20 54 3 15 17 71
Katayama Fever 20 71
Bilharzia 20 3
Schistosoma Mansoni Infection 20
Schistosomiasis Mansoni 71
Blood Fluke 20

Classifications:



External Ids:

Disease Ontology 12 DOID:1395
ICD9CM 34 120.8
SNOMED-CT 67 187116001
UMLS 71 C0029827 C0036323 C0036330 more

Summaries for Schistosomiasis

GARD : 20 Schistosomiasis is a disease caused by parasitic worms. Although the worms that cause schistosomiasis are not found in the United States, more than 200 million people are infected worldwide. Infection occurs through contact with contaminated water. The parasite in its infective stages is called a cercaria. It swims freely in open bodies of water. On contact with humans, the parasite burrows into the skin, matures into another stage (schistosomula), then migrates to the lungs and liver, where it matures into the adult form. The adult worm then migrates to its preferred body part (bladder, rectum, intestines, liver, portal venous system (the veins that carry blood from the intestines to liver, spleen, lungs), depending on its species. Schistosomiasis is common in many tropical and subtropical areas worldwide. It can be treated safely and effectively with praziquantel.

MalaCards based summary : Schistosomiasis, also known as katayama fever, is related to urinary schistosomiasis and intestinal schistosomiasis. An important gene associated with Schistosomiasis is IL4 (Interleukin 4), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Albendazole and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and spinal cord, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves infection of the intestine, urinary tract, skin, liver and spleen caused by multiple species of the trematode fluke of the genus Schistosoma. The symptoms include fever, chills, nausea, abdominal pain, diarrhea, malaise, myalgia, liver and spleen enlargement, rash and hematuria.

CDC : 3 Schistosomiasis, also known as bilharzia, is a disease caused by parasitic worms. Infection with Schistosoma mansoni, S. haematobium, and S. japonicum causes illness in humans; less commonly, S. mekongi and S. intercalatum can cause disease. Although the worms that cause schistosomiasis are not found in the United States, more than 200 million people are infected worldwide.

Wikipedia : 74 Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms... more...

Related Diseases for Schistosomiasis

Diseases related to Schistosomiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 975)
# Related Disease Score Top Affiliating Genes
1 urinary schistosomiasis 32.7 STAT6 RNASE3 IL5 IL4 IL13 IL10
2 intestinal schistosomiasis 32.5 TNF IL5 IL4 IL2 IL17A IL13
3 portal hypertension 31.5 TNF GPT ALB
4 cytokine deficiency 31.2 IL5 IL13
5 liver cirrhosis 31.2 TNF IL10 GPT GAPDH ALB
6 paragonimiasis 31.2 RNASE3 IL5 IL13 IGHE
7 fascioliasis 31.1 IL10 IFNG GPT ALB
8 myelitis 31.1 TNF IL17A IL10
9 ascaris lumbricoides infection 31.0 IL5 IL13 IFNG
10 hypersplenism 31.0 IL4 IFNG ALB
11 hypereosinophilic syndrome 31.0 RNASE3 IL5 IL4 IL2 IL13 IL10
12 strongyloidiasis 31.0 IL5 IL4 IL13 IGHE IFNG
13 cysticercosis 30.9 IL5 IL4 IL10 IGHE
14 transverse myelitis 30.9 TNF IL17A IL10
15 filarial elephantiasis 30.8 IL5 IL4 IL2 IL13 IL10
16 clonorchiasis 30.8 TNF IL2 IL10 IGHE IFNG
17 allergic disease 30.8 TNF RNASE3 IL5 IL4 IL2 IL13
18 pulmonary hypertension 30.8 TNF IL1A IL13 IL10 ARG1 ALB
19 hepatitis c 30.8 TNF IL10 IFNG GPT
20 filariasis 30.8 TNF IL5 IL2 IL10 IGHE IFNG
21 hepatic encephalopathy 30.8 TNF GPT ALB
22 trichuriasis 30.8 TNF IL13 IL10
23 vaginal discharge 30.8 TNF IL10 ALB
24 volvulus of midgut 30.8 IL5 GPT ALB
25 onchocerciasis 30.7 RNASE3 IL5 IL4 IL2 IL13 IGHE
26 hepatitis b 30.7 TNF IFNGR1 IFNG GPT ALB
27 appendicitis 30.7 TNF IL2 IL17A IL10 IFNG ALB
28 plague 30.7 TNF IL2 IL10 ALB
29 viral hepatitis 30.6 TNF IL4 IL2 IL10 IFNG GPT
30 echinococcosis 30.6 TNF RNASE3 IL5 IL17A IL10 IFNG
31 urticaria 30.6 TNF RNASE3 IL5 IL4 IL13 IGHE
32 diarrhea 30.6 TNF IL5 IL2 IL13 IL10 IFNG
33 toxoplasmosis 30.6 TNF IL5 IL4 IL10 IFNG CD40LG
34 dysentery 30.6 TNF IL1A IL10 GPT ALB
35 plasmodium falciparum malaria 30.5 TNF IL4 IL10 IFNG
36 bacterial vaginosis 30.5 TNF IL4 IL1A IL10
37 opisthorchiasis 30.5 TNF IL4 GPT
38 acute cystitis 30.5 TNF IL10 GPT ALB
39 endomyocardial fibrosis 30.5 TNF RNASE3 IL5 IL4 IL10
40 toxocariasis 30.5 RNASE3 IL5 IL4 IL13 IL10 IGHE
41 cystitis 30.4 TNF IL4 IL2 IL1A IL17A
42 trichinosis 30.4 IL5 IL4 IL17A IL13 IL10
43 disseminated intravascular coagulation 30.4 TNF IL10 GPT
44 loiasis 30.4 IL5 IL4 IL13 IL10
45 giardiasis 30.4 IL17A IL10 ALB
46 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.4 IL17A IL10 IFNG
47 peritonitis 30.4 TNF IL4 IL10 ALB
48 chagas disease 30.4 TNF IL4 IL2 IL17A IL10 IFNG
49 cystic echinococcosis 30.4 RNASE3 IL17A IL10 IFNG
50 typhoid fever 30.4 TNF IL1A IFNGR1 IFNG GPT ALB

Graphical network of the top 20 diseases related to Schistosomiasis:



Diseases related to Schistosomiasis

Symptoms & Phenotypes for Schistosomiasis

MGI Mouse Phenotypes related to Schistosomiasis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 ALB ARG1 CD40LG GAPDH IFNG IFNGR1
2 hematopoietic system MP:0005397 10.37 ARG1 CD40LG GAPDH IFNG IFNGR1 IL10
3 immune system MP:0005387 10.33 ALB ARG1 CD40LG IFNG IFNGR1 IL10
4 endocrine/exocrine gland MP:0005379 10.25 ALB CD40LG IFNG IFNGR1 IL10 IL13
5 digestive/alimentary MP:0005381 10.22 ALB IFNG IFNGR1 IL10 IL13 IL17A
6 liver/biliary system MP:0005370 10.18 ALB ARG1 GAPDH IFNG IFNGR1 IL10
7 integument MP:0010771 10.13 CD40LG IFNG IFNGR1 IL10 IL13 IL17A
8 neoplasm MP:0002006 10.02 ALB IFNG IFNGR1 IL10 IL1A IL2
9 renal/urinary system MP:0005367 9.91 ALB CD40LG GAPDH IFNG IFNGR1 IL17A
10 no phenotypic analysis MP:0003012 9.87 IFNG IL10 IL13 IL17A IL2 IL4
11 reproductive system MP:0005389 9.85 CD40LG IFNG IFNGR1 IL10 IL13 IL2
12 respiratory system MP:0005388 9.61 IFNG IL10 IL13 IL17A IL2 IL4
13 skeleton MP:0005390 9.32 CD40LG GPT IFNG IFNGR1 IL10 IL13

Drugs & Therapeutics for Schistosomiasis

Drugs for Schistosomiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Albendazole Approved, Vet_approved Phase 3 54965-21-8 2082
2
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
3
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
4
Triclabendazole Approved, Investigational Phase 3 68786-66-3
5
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
6
Mefloquine Approved, Investigational Phase 3 53230-10-7 4046
7
Artesunate Approved, Investigational Phase 3 88495-63-0 6917864 5464098
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
9
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
10 Antimitotic Agents Phase 3
11 Tubulin Modulators Phase 3
12 Folic Acid Antagonists Phase 3
13 Vitamin B Complex Phase 3
14 Folate Phase 3
15 Fanasil, pyrimethamine drug combination Phase 3
16 Vitamin B9 Phase 3
17 Antiprotozoal Agents Phase 3
18 Antimalarials Phase 3
19 Antiviral Agents Phase 3
20
Artemether Approved Phase 2 71963-77-4 119380 9796294 68911
21
Lumefantrine Approved Phase 2 82186-77-4 6437380
22
Epoprostenol Approved Phase 2 61849-14-7, 35121-78-9 5280427 5282411
23
Selexipag Approved Phase 2 475086-01-2
24
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
25
Pyronaridine Investigational Phase 2 74847-35-1 5485198
26 Tezosentan Investigational Phase 2 180384-57-0
27
Imidazole Experimental, Investigational Phase 1, Phase 2 288-32-4 795
28 Artemisinine Phase 2
29 Artemisinins Phase 2
30 Artemether, Lumefantrine Drug Combination Phase 2
31 Ferroquine Phase 2
32 Antihypertensive Agents Phase 2
33 Gastrointestinal Agents Phase 1, Phase 2
34 Immunologic Factors Phase 1, Phase 2
35 Antacids Phase 1, Phase 2
36 Adjuvants, Immunologic Phase 1, Phase 2
37 Anti-Ulcer Agents Phase 1, Phase 2
38 Vaccines Phase 1, Phase 2
39 Pharmaceutical Solutions Phase 1, Phase 2
40
Aluminum sulfate Approved Phase 1 10043-01-3
41 Immunoglobulins Phase 1
42 Antibodies Phase 1
43
Sodium citrate Approved, Investigational 68-04-2
44 Mango Approved
45
Iron Approved 7439-89-6 23925 29936
46
Ethanolamine oleate Approved 2272-11-9
47
Cefuroxime Approved 55268-75-2 5361202 5479529
48
Doxycycline Approved, Investigational, Vet_approved 564-25-0 54671203
49
Ciprofloxacin Approved, Investigational 85721-33-1 2764
50
Metronidazole Approved 443-48-1 4173

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology Completed NCT02878564 Phase 4 Praziquantel
3 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
4 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
5 Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar: a Randomized Controlled Trial Unknown status NCT03133832 Phase 3 Companion Tablet
6 Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial Completed NCT01722539 Phase 3 Sulfadoxine-pyrimethamine;Piperaquine;Albendazole;Praziquantel
7 Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study Completed NCT01529710 Phase 3 Myrrh
8 Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire Completed NCT02868385 Phase 3 4x Praziquantel;1x Praziquantel
9 Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel Completed NCT01558336 Phase 3 praziquantel
10 Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children Completed NCT00870649 Phase 3
11 Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Completed NCT04115072 Phase 2, Phase 3 Praziquantel 600Mg Oral Tablet x 5;Praziquantel 600Mg Oral Tablet x 1
12 An Open Label, Phase III Efficacy and Safety Study of L Praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®) Recruiting NCT03845140 Phase 3 L-PZQ ODT;Biltricide®;L-PZQ ODT
13 Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon Recruiting NCT03779347 Phase 3 Praziquantel
14 A Proof-of-concept Trial to Evaluate Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children Active, not recruiting NCT03893097 Phase 3 Praziquantel;Artesunate + Mefloquine
15 Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines. Completed NCT01901484 Phase 2 Praziquantel
16 Activity of Mefloquine Against Urinary Schistosomiasis Completed NCT01132248 Phase 2 Mefloquine;S/P
17 Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection Completed NCT04264130 Phase 2 Artesunate-Pyronaridine;Artemether-Lumefantrine;Artefenomel-Ferroquine
18 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S. Mansoni and/or S. Haematobium. A Comparative, Randomized, Controlled, Open-label Trial Completed NCT03799510 Phase 2 GLA-SE solution
19 Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2) Completed NCT02806232 Phase 2 Biltricide (racemate praziquantel) oral tablets;Racemate Praziquantel ODT;Levo Praziquantel ODT
20 S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT) Completed NCT00486863 Phase 2 Praziquantel
21 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial Completed NCT03041766 Phase 2 GLA-SE solution
22 Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Recruiting NCT04589390 Phase 2 Selexipag
23 A Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of the Sm-TSP-2/Alhydrogel® Schistosomiasis Vaccine in Healthy Exposed Ugandan Adults Recruiting NCT03910972 Phase 1, Phase 2
24 Phase II PK/PD Driven Dose Finding Trial of Praziquantel in Children Under Four Not yet recruiting NCT03640377 Phase 2 Praziquantel
25 A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Completed NCT03110757 Phase 1
26 A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Completed NCT02337855 Phase 1
27 A Phase I Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Combination of DNA-HIV-PT123 and AIDSVAX®B/Ein HIV-1-uninfected Adult Participants With or Without Underlying Schistosoma Mansoni Infection Completed NCT02376582 Phase 1
28 Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis Completed NCT01512277 Phase 1
29 Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Completed NCT01154049 Phase 1
30 Praziquantel Pharmacokinetics in Pregnancy and During Lactation Completed NCT01288872 Phase 1 Praziquantel
31 Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial Unknown status NCT01869465
32 Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. Unknown status NCT01541631 Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole
33 Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas Unknown status NCT03158298
34 Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver. Unknown status NCT01260012
35 Evaluation of Applicability of Urine Based Schistosomiasis Test Strip in the Epidemiologic Mapping and Sampling of Schistosoma Mansoni Infection in Low Endemic Areas of Kenya Completed NCT00463307
36 Women and Childres at the Focal Point for the Schistosomiasis Control and Sustainability and Effectiveness in the Hydro Agricultural Zone of Sourou, Burkina Faso Completed NCT00463528
37 Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Completed NCT00463632
38 Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Completed NCT00463593
39 Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment Completed NCT00414479 praziquantl, iron, ACT
40 Treatment of Schistosomal Portal Hypertension: Assessment of Efficacy of Endoscopic Therapy Alone or in the Combined With Surgical Procedure Completed NCT01931826
41 Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children Completed NCT02144389 Praziquantel (PZQ)
42 A Randomized Control Study to Evaluate Novel Interventions to Reduce Risk Factors Associated With HIV, Neglected Tropical and Non-communicable Diseases Among Couples in Zambia Completed NCT02744586
43 Village Surveys of Morbidity Due to S. Haematobium for 1U01AI4547 Urinary Schistosomiasis-Determinants of Infection and Disease Completed NCT00138450
44 Study of Reproductive Health in Rural Madagascar With Emphasis on Urogenital Schistosomiasis and Sexually Transmitted Infections Completed NCT00713999 Treatment with anti-STI and anti-schistosoma regimens
45 Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Completed NCT01424410
46 Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding Completed NCT02755324
47 Using Community-Based Volunteers to Reach Non-Enrolled School-Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Completed NCT00463931
48 Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Completed NCT00276224 ferrous sulphate (drug)
49 Comparison of Schistosomiasis Diagnostic Techniques and Study of Schistosoma Infection on Children's Immune Response to Childhood Vaccines, on Anaemia and on Nutritional Status Completed NCT01553552
50 Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Completed NCT02495909

Search NIH Clinical Center for Schistosomiasis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Oxamniquine
Praziquantel

Genetic Tests for Schistosomiasis

Anatomical Context for Schistosomiasis

MalaCards organs/tissues related to Schistosomiasis:

40
Liver, Spleen, Spinal Cord, Skin, T Cells, Colon, Kidney

Publications for Schistosomiasis

Articles related to Schistosomiasis:

(show top 50) (show all 16671)
# Title Authors PMID Year
1
Arginase I suppresses IL-12/IL-23p40-driven intestinal inflammation during acute schistosomiasis. 61 54
20483789 2010
2
Transforming growth factor-beta and Th17 responses in resistance to primary murine schistosomiasis mansoni. 54 61
19717308 2009
3
[The role of TGFbeta1 and IL-13 in cellular signal transduction of hepatic fibrosis of schistosomiasis]. 61 54
20066997 2009
4
Antioxidant status and lipid peroxidation activity in evaluating hepatocellular damage in children. 54 61
20187535 2009
5
Immunoglobulin E (IgE) responses to paramyosin predict resistance to reinfection with Schistosoma japonicum and are attenuated by IgG4. 54 61
19273558 2009
6
Association of the gene polymorphisms IFN-gamma +874, IL-13 -1055 and IL-4 -590 with patterns of reinfection with Schistosoma mansoni. 54 61
19190772 2009
7
Circulating CD23+ B cell subset correlates with the development of resistance to Schistosoma mansoni reinfection in occupationally exposed adults who have undergone multiple treatments. 61 54
19072134 2009
8
Genetic polymorphism of glutathione-S-transferase (GST-M1 and GST-T1) in schistosomiasis -associated bladder cancer in Egyptian patients. 61 54
19209780 2008
9
IL-4 and reactive oxygen species are elevated in Egyptian patients affected with schistosomal liver disease. 61 54
19067841 2008
10
Discriminating acute from chronic human schistosomiasis mansoni. 61 54
18851939 2008
11
Eosinophil activation status, cytokines and liver fibrosis in Schistosoma mansoni infected patients. 61 54
18550021 2008
12
Cytokines, chemokine receptors, CD4+CD25HIGH+ T-cells and clinical forms of human schistosomiasis. 54 61
18534548 2008
13
Cytokine profile associated with chronic and acute human schistosomiasis mansoni. 54 61
18949326 2008
14
Eosinophil cationic protein, soluble egg antigen, circulating anodic antigen, and egg excretion in male urogenital schistosomiasis. 54 61
18784236 2008
15
Schistosomiasis and infection with human immunodeficiency virus 1 in rural Zimbabwe: systemic inflammation during co-infection and after treatment for schistosomiasis. 54 61
18784223 2008
16
sTNFR-II and sICAM-1 are associated with acute disease and hepatic inflammation in schistosomiasis japonica. 61 54
18001742 2008
17
Proteases from Schistosoma mansoni cercariae cleave IgE at solvent exposed interdomain regions. 54 61
17631966 2008
18
Treatment of human acute schistosomiasis with oxamniquine induces an increase in interferon-gamma response to Schistosoma mansoni antigens. 61 54
17426890 2007
19
Schistosome membrane proteins as vaccines. 54 61
17222846 2007
20
Changes in the humoral immune responses after chemotherapy in single and co-infected individuals with Schisosoma haematobium and Plasmodium falciparum. 54 61
20353134 2006
21
The role of chemokines in Schistosoma mansoni infection: insights from human disease and murine models. 61 54
17308793 2006
22
Cloning the genes and DNA binding properties of High Mobility Group B1 (HMGB1) proteins from the human blood flukes Schistosoma mansoni and Schistosoma japonicum. 61 54
16644144 2006
23
Skin test reactivity and Der p-induced interleukin 10 production in patients with asthma or rhinitis infected with Ascaris. 54 61
16729785 2006
24
Some molecular aspects in schistosomiasis mansoni and toxoplasmosis. 61 54
16333889 2005
25
De-glycosylation of Pichia pastoris-produced Schistosoma mansoni cathepsin B eliminates non-specific reactivity with IgG in normal human serum. 54 61
16125194 2005
26
Detection of IgG binding to Schistosoma mansoni recombinant protein RP26 is a sensitive and specific method for acute schistosomiasis diagnosis. 61 54
15710554 2005
27
Human T cell epitope mapping of the Schistosoma mansoni 14-kDa fatty acid-binding protein using cells from patients living in areas endemic for schistosomiasis. 61 54
15725385 2005
28
Interleukin (IL)-4, IL-10, IL-18 and IFN-gamma cytokines pattern in patients with combined hepatitis C virus and Schistosoma mansoni infections. 54 61
15644127 2005
29
Production of interferon-gamma by natural killer cells and aging in chronic human schistosomiasis. 61 54
15770048 2004
30
Interleukin-13 in the skin and interferon-gamma in the liver are key players in immune protection in human schistosomiasis. 61 54
15361241 2004
31
[The clinical significance of interferon-gamma and its receptor in patients with schistosomiasis]. 54 61
15830877 2004
32
HTLV-1 modifies the clinical and immunological response to schistosomiasis. 61 54
15270862 2004
33
Chemotherapy for schistosomiasis in Ugandan fishermen: treatment can cause a rapid increase in interleukin-5 levels in plasma but decreased levels of eosinophilia and worm-specific immunoglobulin E. 61 54
15213147 2004
34
Schistosoma mansoni PIII antigen modulates in vitro granuloma formation by regulating CD28, CTLA-4, and CD86 expression in humans. 54 61
15019278 2004
35
Different cytokine patterns in patients coinfected with hepatitis C virus and Schistosoma mansoni. 54 61
15724383 2004
36
Clinical and immunological consequences of human T cell leukemia virus type-I and Schistosoma mansoni co-infection. 54 61
15486648 2004
37
Immunoblot analysis of Schistosoma japonicum egg antigens with sera from patients with acute and chronic schistosomiasis japonica. 54 61
15115074 2003
38
IFN-gamma polymorphisms (IFN-gamma +2109 and IFN-gamma +3810) are associated with severe hepatic fibrosis in human hepatic schistosomiasis (Schistosoma mansoni). 54 61
14607968 2003
39
Assessment of eosinophil cationic protein as a possible diagnostic marker for female genital schistosomiasis in women living in a Schistosoma haematobium endemic area. 54 61
15053779 2003
40
Malaria co-infection in children influences antibody response to schistosome antigens and inflammatory markers associated with morbidity. 61 54
15228260 2003
41
Enhanced interleukin-12 and CD40 ligand activities but reduced Staphylococcus aureus Cowan 1-induced responses suggest a generalized and progressively impaired type 1 cytokine pattern for human schistosomiasis. 54 61
12379664 2002
42
P38 mitogen-activated protein kinase influence on the production of IL-10 in human schistosomiasis mansoni. 54 61
12654092 2002
43
Assessing the morbidity of schistosomiasis by measuring eosinophil cationic protein in serum. 61 54
12214929 2002
44
Polarized Th2 like cells, in the absence of Th0 cells, are responsible for lymphocyte produced IL-4 in high IgE-producer schistosomiasis patients. 61 54
12100735 2002
45
Description of three new polymorphisms in the intronic and 3'UTR regions of the human interferon gamma gene. 61 54
11857052 2002
46
Studies on the production and regulation of interleukin, IL-13, IL-4 and interferon-gamma in human Schistosomiasis mansoni. 61 54
12426605 2002
47
Performance of IgG avidity in an area endemic for schistosomiasis in Egypt. 54 61
15330573 2002
48
Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. 54 61
11756987 2002
49
IgG anti-IgE autoantibodies in visceral leishmaniasis. 54 61
11992157 2002
50
Immunoglobulin-E and anti-IgE treatment in lung disease. 61 54
11980283 2001

Variations for Schistosomiasis

Expression for Schistosomiasis

Search GEO for disease gene expression data for Schistosomiasis.

Pathways for Schistosomiasis

Pathways related to Schistosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 TNF STAT6 RNASE3 LGMN IL5 IL4
2
Show member pathways
13.88 TNF STAT6 IL5 IL4 IL2 IL1A
3
Show member pathways
13.75 TNF IL5 IL4 IL2 IL1A IL17A
4
Show member pathways
13.62 TNF STAT6 IL5 IL4 IL2 IL1A
5
Show member pathways
13.5 TNF STAT6 IL5 IL4 IL2 IL1A
6
Show member pathways
13.42 TNF STAT6 IL5 IL4 IL2 IL1A
7
Show member pathways
13.38 TNF IL5 IL4 IL2 IL1A IL17A
8
Show member pathways
13.27 TNF STAT6 IL4 IL2 IL1A IFNGR1
9
Show member pathways
13.1 TNF STAT6 IL2 IL10 IFNGR1 IFNG
10 12.96 STAT6 IL5 IL4 IL2 IL13 IFNGR1
11
Show member pathways
12.85 TNF IL2 IL1A IFNGR1 IFNG
12
Show member pathways
12.76 TNF IL4 IL2 IL10 IGHE IFNGR1
13
Show member pathways
12.72 TNF IL1A IFNGR1 IFNG CD40LG
14
Show member pathways
12.69 TNF STAT6 IL2 IL17A IL10 IFNG
15 12.68 TNF STAT6 IL4 IL2 IL17A IL10
16
Show member pathways
12.68 TNF RNASE3 LGMN IL5 IL4 IL2
17
Show member pathways
12.65 TNF IL5 IL4 IL13 IGHE
18
Show member pathways
12.64 TNF IL5 IL4 IL2 IL1A IL17A
19
Show member pathways
12.58 TNF IL4 IL2 IFNGR1 IFNG
20
Show member pathways
12.52 STAT6 IL5 IL4 IL2 IL13 IL10
21
Show member pathways
12.45 TNF IL5 IL4 IL17A IL13 IFNG
22
Show member pathways
12.42 TNF IL4 IL2 IFNG ALB
23
Show member pathways
12.4 TNF IL4 IL1A IL10 IFNGR1 IFNG
24
Show member pathways
12.37 TNF IL5 IL4 IL2 IL1A IL17A
25 12.34 TNF IL1A IL10 IFNGR1 IFNG
26
Show member pathways
12.31 TNF STAT6 IL1A IFNGR1 IFNG
27 12.28 TNF IL1A IL13 IL10 GAPDH
28
Show member pathways
12.25 TNF IL4 IFNGR1 IFNG
29
Show member pathways
12.23 TNF STAT6 IL5 IL4 IL2 IL1A
30 12.17 TNF IL4 IL2 IL1A IFNG ARG1
31 12.16 TNF IL1A IFNG GSTM1
32 12.14 TNF IL5 IL4 IL2 IL10 IFNG
33 12.12 TNF IL1A IFNGR1 IFNG
34
Show member pathways
12.1 IL5 IL2 IL1A IL13
35
Show member pathways
12.06 STAT6 IL4 IL2 IFNG
36 12.03 TNF STAT6 IL4 IL1A IL17A IL13
37 12.01 TNF IL10 IFNG ARG1
38 11.99 TNF IL5 IL4 IL1A
39 11.96 TNF IL1A IL17A IFNG
40 11.95 IL5 IL4 IL2 IL13 IFNG
41
Show member pathways
11.91 TNF IL2 IL17A IL10 IFNGR1 IFNG
42
Show member pathways
11.89 TNF IL5 IL4 IL2 IFNG CD40LG
43 11.86 TNF IL2 IL10 IFNG
44 11.85 TNF IL5 IL4 IL10 CD40LG
45
Show member pathways
11.82 TNF IL2 IL1A IFNG CD40LG
46 11.8 TNF IL1A IL10
47 11.78 TNF IL5 IL4 IL13
48 11.78 STAT6 IL5 IL4 IL10 IGHE CD40LG
49 11.77 STAT6 IL4 IL2
50 11.76 TNF IL5 IL4 IL2 IL17A IL13

GO Terms for Schistosomiasis

Cellular components related to Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 TNF RNASE3 LGMN IL5 IL4 IL2
2 external side of plasma membrane GO:0009897 9.55 TNF IL17A IL13 IGHE CD40LG
3 extracellular space GO:0005615 9.47 TNF RNASE3 IL5 IL4 IL2 IL1A

Biological processes related to Schistosomiasis according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 TNF STAT6 IL4 IL2 IL1A IL17A
2 adaptive immune response GO:0002250 10.09 IL2 IL17A IGHE IFNG ARG1
3 positive regulation of gene expression GO:0010628 10.05 TNF IL4 IL1A IL13 IFNGR1 IFNG
4 inflammatory response GO:0006954 9.97 TNF IL5 IL1A IL17A IL13 CD40LG
5 cellular response to lipopolysaccharide GO:0071222 9.96 TNF IL1A IL10 ARG1
6 negative regulation of inflammatory response GO:0050728 9.93 IL4 IL2 IL13 IL10
7 B cell differentiation GO:0030183 9.87 IL4 IL10 CD40LG
8 positive regulation of T cell proliferation GO:0042102 9.85 IL4 IL2 CD40LG
9 positive regulation of interleukin-1 beta production GO:0032731 9.85 TNF IL17A IFNG
10 positive regulation of interleukin-6 production GO:0032755 9.84 TNF IL1A IL17A IFNG
11 positive regulation of tumor necrosis factor production GO:0032760 9.83 IL1A IL17A IFNGR1 IFNG
12 positive regulation of interleukin-12 production GO:0032735 9.82 IL17A IFNG CD40LG
13 positive regulation of interleukin-10 production GO:0032733 9.81 IL4 IL13 CD40LG
14 negative regulation of endothelial cell apoptotic process GO:2000352 9.81 IL4 IL13 IL10
15 positive regulation of JAK-STAT cascade GO:0046427 9.77 TNF IL5 IL10
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 TNF IL4 IL2 IL13 IFNG
17 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.76 IL4 IL2 IL1A
18 positive regulation of osteoclast differentiation GO:0045672 9.72 TNF IL17A IFNG
19 positive regulation of B cell proliferation GO:0030890 9.71 IL5 IL4 IL2 IL13
20 positive regulation of podosome assembly GO:0071803 9.7 TNF IL5
21 immune response GO:0006955 9.7 TNF IL5 IL4 IL2 IL1A IL17A
22 negative regulation of T-helper 17 cell differentiation GO:2000320 9.69 IL4 IL2
23 positive regulation of isotype switching to IgG isotypes GO:0048304 9.69 IL4 IL2
24 positive regulation of mast cell degranulation GO:0043306 9.69 IL4 IL13
25 positive regulation of amyloid-beta formation GO:1902004 9.69 TNF IFNGR1 IFNG
26 regulation of immunoglobulin production GO:0002637 9.68 TNF CD40LG
27 endothelial cell apoptotic process GO:0072577 9.68 TNF IL10
28 positive regulation of mononuclear cell migration GO:0071677 9.67 TNF IL4
29 negative regulation of cytokine production involved in immune response GO:0002719 9.67 TNF IL10
30 positive regulation of cellular respiration GO:1901857 9.66 IL4 IFNG
31 neuroinflammatory response GO:0150076 9.65 IL4 IFNG
32 type 2 immune response GO:0042092 9.65 IL4 IL10
33 positive regulation of interleukin-23 production GO:0032747 9.65 IL17A IFNG
34 astrocyte activation GO:0048143 9.65 TNF IFNGR1 IFNG
35 positive regulation of cytokine production GO:0001819 9.65 TNF IL1A IL10 IFNG GAPDH
36 negative regulation of amyloid-beta clearance GO:1900222 9.63 TNF IFNGR1 IFNG
37 negative regulation of complement-dependent cytotoxicity GO:1903660 9.62 IL4 IL13
38 positive regulation of plasma cell differentiation GO:1900100 9.62 IL2 IL10
39 positive regulation of immunoglobulin production GO:0002639 9.62 IL5 IL2 IL13 IL10
40 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IFNG
41 positive regulation of isotype switching to IgE isotypes GO:0048295 9.61 STAT6 IL4
42 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL4 IL10 IFNG
43 regulation of isotype switching GO:0045191 9.6 IL4 IL10
44 positive regulation of vitamin D biosynthetic process GO:0060557 9.57 TNF IFNG
45 positive regulation of nitrogen compound metabolic process GO:0051173 9.56 TNF IFNG
46 microglial cell activation GO:0001774 9.55 TNF IL4 IL13 IFNGR1 IFNG
47 cytokine-mediated signaling pathway GO:0019221 9.36 TNF STAT6 IL5 IL4 IL2 IL1A

Molecular functions related to Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 TNF IL5 IL4 IL2 IL1A IL17A
2 growth factor activity GO:0008083 9.26 IL5 IL4 IL2 IL10

Sources for Schistosomiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....